ALP Bio AG
to accelerate their platform which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
ALP Bio AG has raised €2.1M across 2 funding rounds from 3 investors, most recently a round in Jul 2026. Based in Schlieren, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Schlieren, Switzerlandalp.bio ↗
Total raised
€2.1M
€2,063,221
Funding rounds
2
Investors
3
distinct backers
Active since
2026-04
latest 2026-07
Funding by year
EUR raised per year · 2026 YTDALP Bio AG — funding by year — interactive chart.
Data table
| ALP Bio AG — funding by year | |
|---|---|
| 2026 | €2.1M |
Signals
High confidenceRaise-next likelihood16
base rate 30% for Other
- ▼ Raised very recently
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▼ Young (<3y)
- ▲ Recent equity round, but funding momentum is down (may be rescue financing)
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-03 | Other | €163k | Venture Kick | View deal → |
| 2026-04-30 | Pre-Seed | €1.9M | 42CAP,strategic angel investors,Venture Kick | View deal → |
Investors
3Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData